LivaNova (NASDAQ:LIVN) Price Target Cut to $60.00 by Analysts at Mizuho

LivaNova (NASDAQ:LIVN) had its target price cut by Mizuho from $70.00 to $60.00 in a report released on Wednesday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Mizuho’s price target points to a potential upside of 45.40% from the company’s previous close.

Several other analysts have also recently weighed in on LIVN. Robert W. Baird raised their target price on shares of LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Needham & Company LLC lowered their price objective on LivaNova from $75.00 to $64.00 and set a “buy” rating for the company in a research report on Wednesday. Wolfe Research cut LivaNova from an “outperform” rating to a “peer perform” rating in a research note on Wednesday. StockNews.com upgraded shares of LivaNova from a “buy” rating to a “strong-buy” rating in a research report on Friday, February 14th. Finally, Stifel Nicolaus reduced their price target on shares of LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research report on Wednesday. Two equities research analysts have rated the stock with a hold rating, five have given a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Buy” and an average target price of $63.67.

LivaNova Trading Down 1.0 %

LivaNova stock traded down $0.44 during trading on Wednesday, hitting $41.27. The company had a trading volume of 404,878 shares, compared to its average volume of 536,281. LivaNova has a 1-year low of $40.37 and a 1-year high of $64.47. The company’s 50 day simple moving average is $47.78 and its 200-day simple moving average is $49.62. The stock has a market cap of $2.24 billion, a price-to-earnings ratio of 98.19 and a beta of 1.00. The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46.

Insider Activity

In other news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the transaction, the director now owns 7,522 shares in the company, valued at $383,546.78. This trade represents a 14.25 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 0.27% of the company’s stock.

Institutional Investors Weigh In On LivaNova

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Russell Investments Group Ltd. grew its holdings in shares of LivaNova by 17.1% in the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock worth $70,000 after acquiring an additional 219 shares during the period. Sterling Capital Management LLC boosted its position in shares of LivaNova by 800.6% in the 4th quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock worth $75,000 after buying an additional 1,441 shares in the last quarter. Central Pacific Bank Trust Division increased its stake in shares of LivaNova by 21.2% during the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after purchasing an additional 720 shares in the last quarter. Captrust Financial Advisors purchased a new stake in shares of LivaNova in the third quarter valued at $217,000. Finally, Sanctuary Advisors LLC acquired a new position in shares of LivaNova in the third quarter valued at approximately $219,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.